No drug currently exists in development that specifically targets CCN1; however, our data are consistent with an emerging hypothesis based on data from several laboratories that suggest blocking CCN1 activity, as CCN1 promotes angiogenesis and ECM alignment may be useful alone, or in a combination therapy with either BRAF or ICIs, to treat melanoma. Here, BRAF is linked to melanoma.